Abstract
Summary
The global market for Chronic Heart Failure (CHF) Devices was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Heart Failure (CHF) Devices, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Chronic Heart Failure (CHF) Devices by region & country, by Type, and by Application.
The Chronic Heart Failure (CHF) Devices market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Heart Failure (CHF) Devices.
Market Segmentation
By Company
Medtronic
Abbott
Johnson & Johnson
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Boston Scientific Corporation
HeartWare
Biovail Corporation
Abiomed
Symplmed Pharmaceuticals
Berlin Heart GmbH
ReliantHeart, Inc.
Cardiokinetix
Biotronik
Jarvik Heart
Segment by Type:
Implantable Left Ventricular Assist Device (LVAD)
Biventricular Pacemaker
Implantable Cardioverter-defibrillators (ICDs)
Continuous Positive Air Pressure Device (CPAP)
Bi-level Positive Air Pressure Device (BiPAP)
Heart Pumps
Segment by Application
Hospital
Clinic
Household
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chronic Heart Failure (CHF) Devices manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Chronic Heart Failure (CHF) Devices in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Chronic Heart Failure (CHF) Devices in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Heart Failure (CHF) Devices, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Chronic Heart Failure (CHF) Devices by region & country, by Type, and by Application.
The Chronic Heart Failure (CHF) Devices market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Heart Failure (CHF) Devices.
Market Segmentation
By Company
Medtronic
Abbott
Johnson & Johnson
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Boston Scientific Corporation
HeartWare
Biovail Corporation
Abiomed
Symplmed Pharmaceuticals
Berlin Heart GmbH
ReliantHeart, Inc.
Cardiokinetix
Biotronik
Jarvik Heart
Segment by Type:
Implantable Left Ventricular Assist Device (LVAD)
Biventricular Pacemaker
Implantable Cardioverter-defibrillators (ICDs)
Continuous Positive Air Pressure Device (CPAP)
Bi-level Positive Air Pressure Device (BiPAP)
Heart Pumps
Segment by Application
Hospital
Clinic
Household
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chronic Heart Failure (CHF) Devices manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Chronic Heart Failure (CHF) Devices in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Chronic Heart Failure (CHF) Devices in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Chronic Heart Failure (CHF) Devices Product Introduction
1.2 Global Chronic Heart Failure (CHF) Devices Market Size Forecast
1.2.1 Global Chronic Heart Failure (CHF) Devices Sales Value (2019-2030)
1.2.2 Global Chronic Heart Failure (CHF) Devices Sales Volume (2019-2030)
1.2.3 Global Chronic Heart Failure (CHF) Devices Sales Price (2019-2030)
1.3 Chronic Heart Failure (CHF) Devices Market Trends & Drivers
1.3.1 Chronic Heart Failure (CHF) Devices Industry Trends
1.3.2 Chronic Heart Failure (CHF) Devices Market Drivers & Opportunity
1.3.3 Chronic Heart Failure (CHF) Devices Market Challenges
1.3.4 Chronic Heart Failure (CHF) Devices Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Chronic Heart Failure (CHF) Devices Players Revenue Ranking (2023)
2.2 Global Chronic Heart Failure (CHF) Devices Revenue by Company (2019-2024)
2.3 Global Chronic Heart Failure (CHF) Devices Players Sales Volume Ranking (2023)
2.4 Global Chronic Heart Failure (CHF) Devices Sales Volume by Company Players (2019-2024)
2.5 Global Chronic Heart Failure (CHF) Devices Average Price by Company (2019-2024)
2.6 Key Manufacturers Chronic Heart Failure (CHF) Devices Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Chronic Heart Failure (CHF) Devices Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Chronic Heart Failure (CHF) Devices
2.9 Chronic Heart Failure (CHF) Devices Market Competitive Analysis
2.9.1 Chronic Heart Failure (CHF) Devices Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Chronic Heart Failure (CHF) Devices Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Heart Failure (CHF) Devices as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Implantable Left Ventricular Assist Device (LVAD)
3.1.2 Biventricular Pacemaker
3.1.3 Implantable Cardioverter-defibrillators (ICDs)
3.1.4 Continuous Positive Air Pressure Device (CPAP)
3.1.5 Bi-level Positive Air Pressure Device (BiPAP)
3.1.6 Heart Pumps
3.2 Global Chronic Heart Failure (CHF) Devices Sales Value by Type
3.2.1 Global Chronic Heart Failure (CHF) Devices Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Chronic Heart Failure (CHF) Devices Sales Value, by Type (2019-2030)
3.2.3 Global Chronic Heart Failure (CHF) Devices Sales Value, by Type (%) (2019-2030)
3.3 Global Chronic Heart Failure (CHF) Devices Sales Volume by Type
3.3.1 Global Chronic Heart Failure (CHF) Devices Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Chronic Heart Failure (CHF) Devices Sales Volume, by Type (2019-2030)
3.3.3 Global Chronic Heart Failure (CHF) Devices Sales Volume, by Type (%) (2019-2030)
3.4 Global Chronic Heart Failure (CHF) Devices Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Household
4.1.4 Others
4.2 Global Chronic Heart Failure (CHF) Devices Sales Value by Application
4.2.1 Global Chronic Heart Failure (CHF) Devices Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Chronic Heart Failure (CHF) Devices Sales Value, by Application (2019-2030)
4.2.3 Global Chronic Heart Failure (CHF) Devices Sales Value, by Application (%) (2019-2030)
4.3 Global Chronic Heart Failure (CHF) Devices Sales Volume by Application
4.3.1 Global Chronic Heart Failure (CHF) Devices Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Chronic Heart Failure (CHF) Devices Sales Volume, by Application (2019-2030)
4.3.3 Global Chronic Heart Failure (CHF) Devices Sales Volume, by Application (%) (2019-2030)
4.4 Global Chronic Heart Failure (CHF) Devices Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Chronic Heart Failure (CHF) Devices Sales Value by Region
5.1.1 Global Chronic Heart Failure (CHF) Devices Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Chronic Heart Failure (CHF) Devices Sales Value by Region (2019-2024)
5.1.3 Global Chronic Heart Failure (CHF) Devices Sales Value by Region (2025-2030)
5.1.4 Global Chronic Heart Failure (CHF) Devices Sales Value by Region (%), (2019-2030)
5.2 Global Chronic Heart Failure (CHF) Devices Sales Volume by Region
5.2.1 Global Chronic Heart Failure (CHF) Devices Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Chronic Heart Failure (CHF) Devices Sales Volume by Region (2019-2024)
5.2.3 Global Chronic Heart Failure (CHF) Devices Sales Volume by Region (2025-2030)
5.2.4 Global Chronic Heart Failure (CHF) Devices Sales Volume by Region (%), (2019-2030)
5.3 Global Chronic Heart Failure (CHF) Devices Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
5.4.2 North America Chronic Heart Failure (CHF) Devices Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
5.5.2 Europe Chronic Heart Failure (CHF) Devices Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
5.6.2 Asia Pacific Chronic Heart Failure (CHF) Devices Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
5.7.2 South America Chronic Heart Failure (CHF) Devices Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
5.8.2 Middle East & Africa Chronic Heart Failure (CHF) Devices Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Chronic Heart Failure (CHF) Devices Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Chronic Heart Failure (CHF) Devices Sales Value
6.2.1 Key Countries/Regions Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.2.2 Key Countries/Regions Chronic Heart Failure (CHF) Devices Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.3.2 United States Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.4.2 Europe Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.5.2 China Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.5.3 China Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.6.2 Japan Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.7.2 South Korea Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.8.2 Southeast Asia Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Chronic Heart Failure (CHF) Devices Sales Value, 2019-2030
6.9.2 India Chronic Heart Failure (CHF) Devices Sales Value by Type (%), 2023 VS 2030
6.9.3 India Chronic Heart Failure (CHF) Devices Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Medtronic
7.1.1 Medtronic Company Information
7.1.2 Medtronic Introduction and Business Overview
7.1.3 Medtronic Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Medtronic Chronic Heart Failure (CHF) Devices Product Offerings
7.1.5 Medtronic Recent Development
7.2 Abbott
7.2.1 Abbott Company Information
7.2.2 Abbott Introduction and Business Overview
7.2.3 Abbott Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Abbott Chronic Heart Failure (CHF) Devices Product Offerings
7.2.5 Abbott Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Company Information
7.3.2 Johnson & Johnson Introduction and Business Overview
7.3.3 Johnson & Johnson Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Johnson & Johnson Chronic Heart Failure (CHF) Devices Product Offerings
7.3.5 Johnson & Johnson Recent Development
7.4 Stanley Pharmaceuticals
7.4.1 Stanley Pharmaceuticals Company Information
7.4.2 Stanley Pharmaceuticals Introduction and Business Overview
7.4.3 Stanley Pharmaceuticals Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Stanley Pharmaceuticals Chronic Heart Failure (CHF) Devices Product Offerings
7.4.5 Stanley Pharmaceuticals Recent Development
7.5 New Haven Pharmaceuticals, Inc.
7.5.1 New Haven Pharmaceuticals, Inc. Company Information
7.5.2 New Haven Pharmaceuticals, Inc. Introduction and Business Overview
7.5.3 New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.5.4 New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Devices Product Offerings
7.5.5 New Haven Pharmaceuticals, Inc. Recent Development
7.6 Boston Scientific Corporation
7.6.1 Boston Scientific Corporation Company Information
7.6.2 Boston Scientific Corporation Introduction and Business Overview
7.6.3 Boston Scientific Corporation Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Boston Scientific Corporation Chronic Heart Failure (CHF) Devices Product Offerings
7.6.5 Boston Scientific Corporation Recent Development
7.7 HeartWare
7.7.1 HeartWare Company Information
7.7.2 HeartWare Introduction and Business Overview
7.7.3 HeartWare Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.7.4 HeartWare Chronic Heart Failure (CHF) Devices Product Offerings
7.7.5 HeartWare Recent Development
7.8 Biovail Corporation
7.8.1 Biovail Corporation Company Information
7.8.2 Biovail Corporation Introduction and Business Overview
7.8.3 Biovail Corporation Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Biovail Corporation Chronic Heart Failure (CHF) Devices Product Offerings
7.8.5 Biovail Corporation Recent Development
7.9 Abiomed
7.9.1 Abiomed Company Information
7.9.2 Abiomed Introduction and Business Overview
7.9.3 Abiomed Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Abiomed Chronic Heart Failure (CHF) Devices Product Offerings
7.9.5 Abiomed Recent Development
7.10 Symplmed Pharmaceuticals
7.10.1 Symplmed Pharmaceuticals Company Information
7.10.2 Symplmed Pharmaceuticals Introduction and Business Overview
7.10.3 Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Devices Product Offerings
7.10.5 Symplmed Pharmaceuticals Recent Development
7.11 Berlin Heart GmbH
7.11.1 Berlin Heart GmbH Company Information
7.11.2 Berlin Heart GmbH Introduction and Business Overview
7.11.3 Berlin Heart GmbH Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Berlin Heart GmbH Chronic Heart Failure (CHF) Devices Product Offerings
7.11.5 Berlin Heart GmbH Recent Development
7.12 ReliantHeart, Inc.
7.12.1 ReliantHeart, Inc. Company Information
7.12.2 ReliantHeart, Inc. Introduction and Business Overview
7.12.3 ReliantHeart, Inc. Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.12.4 ReliantHeart, Inc. Chronic Heart Failure (CHF) Devices Product Offerings
7.12.5 ReliantHeart, Inc. Recent Development
7.13 Cardiokinetix
7.13.1 Cardiokinetix Company Information
7.13.2 Cardiokinetix Introduction and Business Overview
7.13.3 Cardiokinetix Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Cardiokinetix Chronic Heart Failure (CHF) Devices Product Offerings
7.13.5 Cardiokinetix Recent Development
7.14 Biotronik
7.14.1 Biotronik Company Information
7.14.2 Biotronik Introduction and Business Overview
7.14.3 Biotronik Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Biotronik Chronic Heart Failure (CHF) Devices Product Offerings
7.14.5 Biotronik Recent Development
7.15 Jarvik Heart
7.15.1 Jarvik Heart Company Information
7.15.2 Jarvik Heart Introduction and Business Overview
7.15.3 Jarvik Heart Chronic Heart Failure (CHF) Devices Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Jarvik Heart Chronic Heart Failure (CHF) Devices Product Offerings
7.15.5 Jarvik Heart Recent Development
8 Industry Chain Analysis
8.1 Chronic Heart Failure (CHF) Devices Industrial Chain
8.2 Chronic Heart Failure (CHF) Devices Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Chronic Heart Failure (CHF) Devices Sales Model
8.5.2 Sales Channel
8.5.3 Chronic Heart Failure (CHF) Devices Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer